Table 3.
Secondary Outcomes of Maternal and Infant Participants in Pilot Randomized Trial of Co-Located and Co-Scheduled Postpartum and Newborn Visits
| Overall, n = 116 | Mommy-baby group, n = 58 | Usual care group, n = 58 | |
|---|---|---|---|
| Infant outcomes | |||
| On-time well-child care, n (%) | 54 (48.2) | 29 (51.8) | 25 (44.6) |
| On-time receipt of vaccines, n (%) | 77 (68.7) | 40 (71.4) | 37 (66.1) |
| No. of acute care visits, mean (SD) | 1.26 (1.56) | 1.18 (1.57) | 1.35 (1.57) |
| No. of ED visits, mean (SD) | 1.30 (1.68) | 1.46 (1.80) | 1.12 (1.56) |
| Maternal outcomes, n (%) | |||
| Contraception | |||
| LARCa started or surgery before discharge | 73 (62.9) | 38 (65.5) | 35 (60.3) |
| Initiating/continuing contraception at postpartum visit | 91 (78.4) | 42 (72.4) | 49 (84.5) |
| Using LARC at 6 months | 69 (59.5) | 33 (56.9) | 36 (62.1) |
| Using LARC at 12 months | 70 (60.3) | 32 (55.2) | 38 (65.5) |
| Health care utilization, n (%) | |||
| Primary care visit within 12 months after delivery | 18 (15.5) | 10 (17.2) | 8 (13.8) |
p > 0.05 for all fields.
a
LARC includes IUD, injectable, implant, tubal ligation, and vasectomy.
ED, Emergency Department; IUD, Intrauterine Device; LARC, long-acting reversible contraception.